Tags: Amgen | biotech | earnings | profit

Amgen’s Profit Rises 21% on Strong Biotech-Drug Sales

Tuesday, 23 Apr 2013 04:33 PM

Biotech giant Amgen Inc. says its first-quarter profit rose 21 percent on higher sales of drugs to treat arthritis and osteoporosis.

The company on Tuesday reported net income of $1.43 billion, or $1.88 per share, from $1.18 billion, or $1.48 per share, in the prior-year period. Adjusted earnings were $1.96 per share.

Revenue rose 5 percent, to $4.24 billion.

Analysts polled by FactSet expect earnings per share of $1.84 on sales of $4.37 billion.

Sales of the Thousand Oaks, Calif., company's biotech drugs were driven by growth of Enbrel for psoriasis and rheumatoid arthritis and Prolia for osteoporosis.

Sales of anemia drugs Aranesp and Epogen continued their long slide due to limits on dosing and reimbursement because of safety concerns.

Shares are off 4.7 percent to $107.42 in after-hours trading.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Companies
Biotech giant Amgen Inc. says its first-quarter profit rose 21 percent on higher sales of drugs to treat arthritis and osteoporosis.
Amgen,biotech,earnings,profit
130
2013-33-23
Tuesday, 23 Apr 2013 04:33 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved